Cartiva Toe Implant Litigation is Centralized
The Cartiva Synthetic Cartilage Implant (Cartiva SCI) is a hydrogel implant created to treat painful toe arthritis at the big toe’s base. Recently, plaintiffs in five lawsuits moved under 28 U.S.C. section 1407 to centralize litigation about Cartiva toe implants in the District of Maryland or the Northern District of Illinois. There are plaintiffs in nine potential tag-along lawsuits in seven districts, and some of them also supported centralization in the Northern District of Illinois. If you were harmed by Cartiva toe implants, you should give the seasoned Chicago- based medical device lawyers of Moll Law Group a call to determine whether you have a viable claim. Billions have been recovered in cases with which we’ve been involved around the country.
Call Moll Law Group About Your Cartiva Claim
Each of the plaintiffs was implanted with the Cartiva Synthetic Cartilage Implant. These implants, which are put in place during a minimally invasive 30-minute outpatient procedure, are supposed to provide a cushioning effect, and allow for the replacement of painful, damaged cartilage without fusion of the joint.
In their lawsuits, the plaintiffs alleged that the implant was defective and that, as a result, they suffered from persistent pain and limited range of motion after being implanted with them and then needed further surgery to remove the failed implants and fuse their arthritic joints. Their claims were for strict product liability, negligence, and breach of express and implied warranties.
Illinois Injury and Mass Tort Lawyer Blog


Manufacturer Medline Industries initiated a
Bard’s PowerPort devices are implanted under the skin and pump intravenous chemotherapy and other fluid into a patient’s bloodstream. These are two-part devices with an injection reservoir and a catheter. Recently, plaintiffs in eight lawsuits against Becton, Dickinson & Company, C.R. Bard, Inc., and Bard Access Systems 